Abstract
Preclinical and clinical data emerging over the past year demonstrate that cancer cells suppress the cytotoxic functions of natural killer cells by a variety of mechanisms. These findings reveal a new arsenal of actionable therapeutic targets to drive clinically relevant immune responses against cancer.
Keywords:
NKG2A; NKG2D; PD-1; durvalumab; immune checkpoint blockers; immunotherapy; monalizumab; pembrolizumab.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antineoplastic Agents, Immunological / pharmacology
-
Antineoplastic Agents, Immunological / therapeutic use
-
Cytotoxicity, Immunologic*
-
Humans
-
Immunotherapy
-
Killer Cells, Natural / drug effects
-
Killer Cells, Natural / immunology*
-
Killer Cells, Natural / metabolism
-
Neoplasms / immunology*
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Neoplasms / therapy
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
T-Lymphocyte Subsets / pathology
-
Tumor Microenvironment
Substances
-
Antineoplastic Agents, Immunological